| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:15941009 | IVR | 60 mg/kg | 60 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations |
| IVR | 180 mg/kg | 180 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:18648085 | IVTH | 0.00003 M | 0.00003 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 400 mg/kg/day | - | No significant effects observed | - | |
| PMID:20132880 | IVR | 1000 mg/kg | 1000 mg/kg | Increased weights of adrenal gland | Metabolic endocrine-mediated perturbations |
| IVR | 62.5 mg/kg | - | No significant effects observed | - | |
| IVR | 250 mg/kg | - | No significant effects observed | - | |
| PMID:34101200 | IVR | 16 mg/kg | 16 mg/kg | Affects fertility | Reproductive endocrine-mediated perturbations |
| IVR | 16 mg/kg | 16 mg/kg | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Affects expression of estrogen receptor (ER) | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 8 - 16 mg/kg | 8 - 16 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Affects uterine function | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations | |
| PMID:35810903 | IVTH | 0.00001 - 0.0005 M | 0.00001 - 0.0005 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:36702264 | IVTH | 0.0001 M | 0.0001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0001 M | 0.0001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.0001 M | 0.00001 - 0.0001 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 M | 0.00001 M | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000005 - 0.001 M | 0.000005 - 0.001 M | Cancer phenotype | Endocrine-mediated cancer |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.